A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT07225569. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 2, Dose-finding Study to Investigate the Efficacy and Safety of SAR445399 in Participants With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis suppurativa. The purpose of this study is to assess the efficacy and safety of two doses of SAR445399 compared with placebo in adult participants with moderate to severe hidradenitis suppurativa. The study duration (per participant) will be up to 46 weeks with a total of 16 visits. The treatment duration will be 32 weeks which includes 16-week double-blinded initial treatment period and a 16-week treatment-blinded extension period.
Study identification
- NCT ID
- NCT07225569
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 144 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 28, 2025
- Primary completion
- Sep 21, 2027
- Completion
- Nov 18, 2027
- Last update posted
- Sep 21, 2026
2025 – 2027
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Clinical Trials- Site Number : 8400006 | Scottsdale | Arizona | 85260 | Recruiting |
| Carbon Health - North Hollywood - NoHo West- Site Number : 8400017 | North Hollywood | California | 91606 | Active, not recruiting |
| Encore Medical Research of Boynton Beach- Site Number : 8400005 | Boynton Beach | Florida | 33436 | Recruiting |
| FXM Clinical Research - Fort Lauderdale- Site Number : 8400013 | Fort Lauderdale | Florida | 33308 | Recruiting |
| Alliance for Multispeciality Research - Fort Myers- Site Number : 8400007 | Fort Myers | Florida | 33912 | Recruiting |
| Encore Medical Research - Hollywood- Site Number : 8400004 | Hollywood | Florida | 33024 | Recruiting |
| Fxm Clinical Research/Fax Pharma Clinical Research- Site Number : 8400014 | Miami | Florida | 33146 | Recruiting |
| Florida International Research Center- Site Number : 8400002 | Miami | Florida | 33173 | Recruiting |
| Florida Research Center- Site Number : 8400009 | Miami | Florida | 33174 | Recruiting |
| Advanced Clinical Research Institute- Site Number : 8400021 | Tampa | Florida | 33607 | Recruiting |
| Cleaver Medical Group Dermatology- Site Number : 8400008 | Cumming | Georgia | 30040 | Recruiting |
| First Georgia Physician Group- Site Number : 8400033 | Fayetteville | Georgia | 30214 | Recruiting |
| NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400019 | Skokie | Illinois | 60077 | Recruiting |
| Deaconess Clinic - Downtown Fourth Street- Site Number : 8400029 | Evansville | Indiana | 47708 | Recruiting |
| Essential Medical Research- Site Number : 8400015 | Overland Park | Kansas | 66213 | Recruiting |
| Dermatology Specialists Research (DS Research) - Kentucky- Site Number : 8400026 | Louisville | Kentucky | 40241 | Recruiting |
| Beth Israel Deaconess Medical Center - Boston- Site Number : 8400001 | Boston | Massachusetts | 02215 | Recruiting |
| University Health Dermatology- Site Number : 8400018 | Kansas City | Missouri | 64108 | Recruiting |
| Equity Medical (LLC)- Site Number : 8400010 | The Bronx | New York | 10455 | Recruiting |
| Elligo Health Research/The Woodlands Dermatology Associates- Site Number : 8400020 | The Woodlands | Texas | 77380 | Recruiting |
| Virginia Dermatology & Skin Cancer Center- Site Number : 8400024 | Norfolk | Virginia | 23502 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07225569, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2026 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07225569 live on ClinicalTrials.gov.